Evaluation of the Efficacy of Probiotics in the Treatment of Infantile Colic: A Randomized, Double Blind, Placebo Controlled Trial
Probiotics in the treatment of infantile colic
The infantile colic is one of the most common complaints in the infancy; however, limited therapeutic approaches are described in the literature. Recently probiotics have been suggested as a potential strategy in the treatment of infantile colic. We conducted this study to investigate the efficacy of probiotics in relieving colic symptoms in Iranian infants. This double-blind clinical trial was performed among 70 infants aged 3 to 16 weeks with the presumed diagnosis of infantile colic according to Wessel criteria who were breastfed or formula fed. They were assigned at random to receive Pedilact® (Bifidobacterium infantis, Lactobacillus reuteri, and Lactobacillus rhamnosus) (N=33) or placebo (N=32). Demographic data were recorded in the questionnaires at the beginning of the study. The number of daily episodes of crying and fussiness, number of weekly crying days, and duration of crying were separately analyzed on 7, 21, and 30th days of investigation. Baseline demographic data showed no statistically significant difference between intervention and placebo groups. Infants given Pedilact® showed a significant reduction in daily episodes of crying, duration of crying, and the weekly number of crying days at the end of the treatment period compared with those receiving placebo (P=0.000). On 21th day of the study, daily episodes of fuss and crying (P=0.032) and duration of crying reduced significantly in the intervention group in comparison to the placebo group (P=0.000). Administration of Pedilact® drop significantly improved colic symptoms by reducing crying and fussing times in breastfed or formula fed in Iranian infants with colic.
2. Lucassen PL, Assendelft WJ, Van Eijk JT, Gubbels JW, Douwes AC, Van Geldrop WJ. Systematic review of the occurrence of infantile colic in the community. Arch Dis Child. 2001; 84(5): 398–403.
3. Talachian E, Bidari A, Rezaie MH. Incidence and risk factors for infantile colic in Iranian infants. World Journal of Gastroenterology. World J Gastroenterol. 2008; 14(29), 4662–4666.
4. Wessel MA, Cobb JC, Jackson EB, Harris GS, Detwiler AC. Paroxysmal fussing in infancy, sometimes called colic. Pediatrics. 1954; 14(5): 421–435.
5. Fujiwara T, Barr RG, Brant R, Barr M. Infant distress at five weeks of age and caregiver frustration. J Pediatr. 2011; 159: 425–430.
6. Talvik I, Alexander RC, Talvik T. Shaken baby syndrome and a baby’s cry. Acta Paediatr. 2008; 97: 782–785.
7. FAO Food and Nutrition Paper. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a joint FAO/WHO expert consultation, 2001. Cordoba, Argentina.
8. Cruchet S, Furnes R, Maruy A, Hebel E, Palacios J, Medina F, et al. The Use of Probiotics in Pediatric Gastroenterology: A Review of the Literature and Recommendations by Latin-American Experts. Paediatr Drugs: 2015; 17(3): 199-216. doi: 10.1007/s40272-015-0124-6.
9. Anabrees J, Indrio F, Paes B, Alfaleh K. Probiotics for infantile colic: a systematic review. BMC Pediatr. 2013; 13: 186. doi: 10.1186/1471-2431-13-186.
10. Savino F, Pelle E, Palumeri E, Oggero R, Miniero R. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics. 2007; 119(1):e124-30.
11. Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, et al. Treating infant colic with the probiotic Lactobacillus reuteri: double-blind, placebo-controlled randomised trial. BMJ. 2014; 1: 348, g2107. doi: 10.1136/bmj.g2107
12. Savino F, Cordisco L, Tarasco V, Palumeri E, Calabrese R, Oggero R, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010; 126(3):e526-533. doi: 10.1542/peds.2010-0433.
13. Schreck Bird A, Gregory PJ, Jalloh MA, Risoldi Cochrane Z, Hein DJ. Probiotics for the Treatment of Infantile Colic: A Systematic Review. J Pharm Pract. 2017; 30(3): 366-74. doi: 10.1177/0897190016634516.
14. Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J pediatr. 2013; 162(2): 257-62. doi: 10.1016/j.jpeds.2012.08.004.
15. Hall B, Chesters J, Robinson A. Infantile colic: a systematic review of medical and conventional therapies. J Paediatr Child Health. 2012; 48 (2), 128-137. doi: 10.1111/j.1440-1754.2011.02061.x.
16. Mi GL, Zhao L, Qiao DD, Kang WQ, Tang MQ, Xu JK. Effectiveness of Lactobacillus reuteri in infantile colic and colicky induced maternal depression: a prospective single blind randomized trial. Antonie van Leeuwenhoek. 2015; 107(6): 1547-1553. doi: 10.1007/s10482-015-0448-9.
17. Xu M, Wang J, Wang N, Sun F, Wang L, Liu XH. The efficacy and safety of the probiotic bacterium Lactobacillus reuteri DSM 17938 for infantile colic: a meta-analysis of randomized controlled trials. PloS one. 2015; 28: 10(10): e0141445. doi: 10.1371/journal.pone.0141445.